CDKN2A and cancer: To confirm the PARIS predictions and test the sensitivity of cancer cells to TYMS inhibition, we treated a panel of cell lines with different CDKN2A genetic backgrounds with increasing doses of PMX (ranging from 10 nM to 15 μM) and measured cell viability as a readout for synthetic lethality.